PL2773360T3 - Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego - Google Patents

Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Info

Publication number
PL2773360T3
PL2773360T3 PL12844799T PL12844799T PL2773360T3 PL 2773360 T3 PL2773360 T3 PL 2773360T3 PL 12844799 T PL12844799 T PL 12844799T PL 12844799 T PL12844799 T PL 12844799T PL 2773360 T3 PL2773360 T3 PL 2773360T3
Authority
PL
Poland
Prior art keywords
nedd8
administration
enzyme inhibitor
activating enzyme
hypomethylating agent
Prior art date
Application number
PL12844799T
Other languages
English (en)
Polish (pl)
Inventor
Peter G. Smith
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Publication of PL2773360T3 publication Critical patent/PL2773360T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12844799T 2011-11-03 2012-11-02 Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego PL2773360T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555049P 2011-11-03 2011-11-03
PCT/US2012/063382 WO2013067396A2 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
EP12844799.2A EP2773360B1 (en) 2011-11-03 2012-11-02 Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Publications (1)

Publication Number Publication Date
PL2773360T3 true PL2773360T3 (pl) 2018-09-28

Family

ID=48193039

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12844799T PL2773360T3 (pl) 2011-11-03 2012-11-02 Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Country Status (23)

Country Link
US (2) US8980850B2 (OSRAM)
EP (1) EP2773360B1 (OSRAM)
JP (2) JP6231988B2 (OSRAM)
KR (1) KR101987861B1 (OSRAM)
CN (1) CN104245699B (OSRAM)
AU (1) AU2012321106C1 (OSRAM)
BR (1) BR112014010699B1 (OSRAM)
CA (1) CA2854461C (OSRAM)
EA (1) EA028380B1 (OSRAM)
ES (1) ES2668272T3 (OSRAM)
GE (1) GEP20196940B (OSRAM)
HK (1) HK1201733A1 (OSRAM)
IL (1) IL232353B (OSRAM)
MA (1) MA35662B1 (OSRAM)
MX (1) MX357835B (OSRAM)
MY (1) MY176125A (OSRAM)
PH (1) PH12014501001B1 (OSRAM)
PL (1) PL2773360T3 (OSRAM)
SG (1) SG11201401895WA (OSRAM)
TN (1) TN2014000194A1 (OSRAM)
TR (1) TR201807342T4 (OSRAM)
UA (1) UA114414C2 (OSRAM)
WO (1) WO2013067396A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1012142A2 (pt) 2009-05-14 2016-03-29 Millennium Pharm Inc sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato
PH12014500419A1 (en) * 2011-08-24 2020-06-22 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
EP2764866A1 (en) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
JP2016525531A (ja) * 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性骨髄性白血病及び骨髄異形成症候群の処置のためのアザシチジンと組み合わせたボラセルチブ
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
WO2018218119A1 (en) * 2017-05-25 2018-11-29 The Board Of Trustees Of The Leland Stanford Junior University Combination of low dose il-2 and an inhibitor of treg il-2r desensitization to treat autoimmune and allergic inflammatory diseases
EP3684363A4 (en) * 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
CA3119781A1 (en) * 2018-11-20 2020-05-28 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
KR20210151833A (ko) 2019-03-15 2021-12-14 풀크럼 쎄러퓨틱스, 인코포레이티드 Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
WO2023242235A1 (en) * 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115007323B (zh) * 2022-06-17 2024-01-23 中南大学 一种抑制矿物中黄铁矿浮选的方法
EP4554608A1 (en) * 2022-07-11 2025-05-21 Westlake University Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
SI1848718T1 (sl) 2005-02-04 2012-12-31 Millennium Pharmaceuticals, Inc. Inhibitorji E1 aktivacijskih enzimov
JP5231251B2 (ja) 2006-02-02 2013-07-10 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
CA2659894C (en) * 2006-08-08 2018-03-27 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of e1 activating enzymes
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
CA2742252A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
JP2011513274A (ja) * 2008-02-26 2011-04-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ モルホリニルアントラサイクリン誘導体および脱メチル化剤を含む、抗腫瘍性組合せ
AU2009246926B2 (en) 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2307002B1 (en) * 2008-06-09 2013-01-02 Cyclacel Limited Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
ES2681529T3 (es) * 2009-03-23 2018-09-13 Ambit Biosciences Corporation Métodos de tratamiento utilizando terapia de combinación
BRPI1012142A2 (pt) 2009-05-14 2016-03-29 Millennium Pharm Inc sal cloridrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-diidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil) metil sulfamato
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
HK1200716A1 (zh) 2011-11-01 2015-08-14 细胞基因公司 使用胞苷類似物的口服製劑治療癌症的方法

Also Published As

Publication number Publication date
US8980850B2 (en) 2015-03-17
JP2015505816A (ja) 2015-02-26
TN2014000194A1 (en) 2015-09-30
TR201807342T4 (tr) 2018-06-21
EP2773360A2 (en) 2014-09-10
CA2854461C (en) 2021-01-19
AU2012321106A1 (en) 2013-05-23
EA028380B1 (ru) 2017-11-30
WO2013067396A3 (en) 2014-10-16
PH12014501001B1 (en) 2018-05-04
JP2018009035A (ja) 2018-01-18
NZ624881A (en) 2016-10-28
AU2012321106B2 (en) 2016-08-04
US20130116208A1 (en) 2013-05-09
MY176125A (en) 2020-07-24
IL232353A0 (en) 2014-06-30
MX357835B (es) 2018-07-26
US20150366886A1 (en) 2015-12-24
MA35662B1 (fr) 2014-11-01
KR20140097229A (ko) 2014-08-06
BR112014010699B1 (pt) 2020-12-15
SG11201401895WA (en) 2014-05-29
MX2014005323A (es) 2014-06-05
UA114414C2 (uk) 2017-06-12
EA201400539A1 (ru) 2014-12-30
CN104245699A (zh) 2014-12-24
GEP20196940B (en) 2019-01-10
CN104245699B (zh) 2017-06-27
WO2013067396A2 (en) 2013-05-10
IL232353B (en) 2018-11-29
JP6231988B2 (ja) 2017-11-15
CA2854461A1 (en) 2013-05-10
PH12014501001A1 (en) 2014-06-09
EP2773360B1 (en) 2018-02-28
HK1201733A1 (en) 2015-09-11
KR101987861B1 (ko) 2019-06-11
AU2012321106C1 (en) 2016-11-24
ES2668272T3 (es) 2018-05-17
BR112014010699A2 (pt) 2017-04-25
EP2773360A4 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
IL232353A0 (en) Administering an inhibitor of the 8nedd hemactab enzyme and a hypomethylated substance
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
ZA201401117B (en) Kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions,and methods of use thereof
EP2721019A4 (en) THERAPEUTIC ACTIVE COMPOSITIONS AND METHOD FOR THEIR USE
GB201411462D0 (en) Prebiotic formulations and methods of use
IL253911A0 (en) Inhibitors of kynurenine-3-monooxygenase, pharmaceutical compositions, and methods of their use
SG11201406948PA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
EP2521551A4 (en) METHOD AND COMPOSITIONS FOR TARGETED ACTIVE DEVELOPMENT
ZA201206223B (en) Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof
ZA201400141B (en) Keto-isovalerate decarboxylase enzymes and methods of use thereof
EP2542074A4 (en) PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
EP2675471A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
EP2790709A4 (en) HEMOSTATIC ACTIVE SUBSTANCES AND METHOD OF USE THEREOF
EP2563372A4 (en) PREBIOTIC FORMULATIONS AND METHODS OF USE
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2714716A4 (en) MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS
EP2635287A4 (en) NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION
AP2014007413A0 (en) Stable dosage forms of arterolane and piperaquine
IL238406A0 (en) Mixed inhibitors of aminopeptidase n and nephrilysin
EP2996773A4 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
WO2012177684A9 (en) Use of caspase 3 activity and its inhibitors
HK1192727A (en) Combination of kanase inhibitors and uses thereof
AU2011903595A0 (en) Anti-thrombotic agent and methods of treatment
GB201112739D0 (en) Production and administration of therapeutic agents